← Back to Search

Tyrosine Kinase Inhibitor

Aumolertinib monotherapy for Non-Small Cell Lung Cancer

Phase 3
Waitlist Available
Research Sponsored by EQRx International, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 years
Awards & highlights

Study Summary

This trial is testing a new cancer drug against other existing treatments to see if it is more effective and has fewer side effects. It will last for about 5 years, and patients can keep receiving the treatment if it is helping them.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (PFS) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary outcome measures
DCR as assessed by the investigator per RECIST v1.1
DOR as assessed by the investigator per RECIST v1.1
DepOR as assessed by the investigator per RECIST v1.1
+17 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Aumolertinib monotherapyExperimental Treatment1 Intervention
Group II: Aumolertinib + platinum-based doublet chemotherapyExperimental Treatment7 Interventions
For adenocarcinoma, either: Aumolertinib + cisplatin with pemetrexed, or Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: Aumolertinib + cisplatin or carboplatin with paclitaxel; Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or Aumolertinib + cisplatin or carboplatin with gemcitabine
Group III: Osimertinib monotherapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
2014
Completed Phase 3
~5250
Cisplatin
2013
Completed Phase 3
~1940
Carboplatin
2014
Completed Phase 3
~6670
Paclitaxel
2011
Completed Phase 4
~5380
Nab paclitaxel
2014
Completed Phase 2
~70
Gemcitabine
2017
Completed Phase 3
~2070

Find a Location

Who is running the clinical trial?

EQRx International, Inc.Lead Sponsor
3 Previous Clinical Trials
12 Total Patients Enrolled

Media Library

Aumolertinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05493501 — Phase 3
Non-Small Cell Lung Cancer Research Study Groups: Aumolertinib monotherapy, Aumolertinib + platinum-based doublet chemotherapy, Osimertinib monotherapy
Non-Small Cell Lung Cancer Clinical Trial 2023: Aumolertinib Highlights & Side Effects. Trial Name: NCT05493501 — Phase 3
Aumolertinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05493501 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locations are responsible for administering this clinical trial?

"The trial is based in four locations: Highlands Oncology Group in Springdale, Arkansas; QCCA - Mission Blood & Cancer in Des Moines, Iowa; SCRI - Tennessee Oncology- Nashville in Nashville, Tennessee; and 5 other sites."

Answered by AI

Are there any long-term repercussions to Aumolertinib?

"Aumolertinib's safety is estimated to be a 3. This drug has progressed to Phase 3 clinical trials, which means that while there is data supporting its efficacy, repeated rounds of testing have also supported its safety."

Answered by AI

Are new recruits being sought for this experiment?

"That is correct. The clinical trial's page on clinicaltrials.gov reveals that the research is ongoing and still looking for 420 individuals from 5 different locations."

Answered by AI
~4 spots leftby Mar 2025